SCHEMBL3247337

SCHEMBL3247337

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1nccc(-c2ccnc3[nH]ccc23)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIKFYVE Q9Y2I7 2/20 0.65
▸ KDR P35968 4/20 0.56
▸ TEK Q02763 2/20 0.56
▸ ABL1 P00519 6/20 0.54
▸ BRAF P15056 9/20 0.54
▸ CSF1R P07333 3/20 0.54
▸ KIT P10721 2/20 0.54
▸ LCK P06239 2/20 0.54
▸ SRC P12931 2/20 0.54
▸ MAPK14 Q16539 2/20 0.54
▸ AURKA O14965 1/20 0.54
▸ AURKB Q96GD4 1/20 0.54
▸ TPX2 Q9ULW0 1/20 0.54
▸ PDGFRB P09619 2/20 0.53
▸ PDGFRA P16234 2/20 0.53
▸ EGFR P00533 1/20 0.53
▸ BCR P11274 1/20 0.53
▸ PRKCA P17252 1/20 0.53
▸ RAF1 P04049 1/20 0.52
▸ BTK Q06187 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250300 0.90 KDR (0.59) PIKFYVEKDRTEKABL1BRAF
SCHEMBL3247127 0.85 PIKFYVE (0.62) PIKFYVEKDRTEKABL1BRAF
SCHEMBL2945981 0.84 BRAF (0.68) PIKFYVEKDRTEKABL1BRAF
SCHEMBL2945359 0.83 ABL1 (0.70) PIKFYVEKDRTEKABL1BRAF
SCHEMBL1408815 0.83 ABL1 (0.77) PIKFYVEKDRABL1BRAFCSF1R
SCHEMBL4787643 0.82 BRAF (0.70) PIKFYVEKDRABL1BRAFCSF1R
SCHEMBL30899721 0.81 ABL1 (0.67) PIKFYVEKDRTEKABL1BRAF
SCHEMBL2941693 0.81 ABL1 (0.67) PIKFYVEKDRTEKABL1BRAF
SCHEMBL2940451 0.81 ABL1 (0.59) PIKFYVEKDRTEKABL1BRAF
SCHEMBL1415439 0.81 ABL1 (0.74) PIKFYVEKDRABL1BRAFCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101218241-B Pyrrolopyridine derivatives as protein kinase inhibitors IRM LLC 2011-02-16 — — CN claimed
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 — — EP claimed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 — — US claimed
CN-101218241-A Pyrrolopyridine derivatives as protein kinase inhibitors IRM LLC (BM) 2008-07-09 — — CN claimed
EP-1896470-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-03-12 — — EP claimed
WO-2006124863-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-11-23 — — WO claimed
CN-101218241-B Pyrrolopyridine derivatives as protein kinase inhibitors IRM LLC 2011-02-16 — — CN disclosed
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 — — EP disclosed
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 — — EP disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 — — US disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 — — US disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 — — US disclosed
CN-101218241-A Pyrrolopyridine derivatives as protein kinase inhibitors IRM LLC (BM) 2008-07-09 — — CN disclosed
EP-1896470-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-03-12 — — EP disclosed
WO-2006124863-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors ERBB2, JAK2, AURKC PIKFYVE 157/4885KDR 26/4885TEK 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback